Last updated 2026-07-26
- Acquired by Merck for $605M, Jul 2015
- Raised $8M Series A led by OrbiMed, Aug 2012
Total raised
$8.0M
Last: Undisclosed Round 2012-09
Stage
Acquired
Founded
2010
Headcount
1-10
HQ
Misgav, Israel
Sector
—
About
cCAM Biotherapeutics was an Israeli biopharmaceutical company focused on the discovery and development of novel cancer immunotherapies. Their lead product, CM-24, was a humanized monoclonal antibody targeting the immune checkpoint protein CEACAM1, designed to stimulate the patient's own immune system to attack tumor cells.
Funding history · 1 round · $8.0M total
2012-08
A Round
$8.0M
★ OrbiMed★ Pontifax★ Arkin Tech
Headcount over time
From 1 (2019-02) to 1 (2024-08) · +0 (+0%) · 2 points · source: Finder history + radar grounding
Q&A
- What is cCAM Biotherapeutics' primary focus?
- cCAM Biotherapeutics was an Israeli biopharmaceutical company focused on the discovery and development of novel cancer immunotherapies.
- When was cCAM Biotherapeutics acquired and by whom?
- cCAM Biotherapeutics was acquired by Merck in July 2015 for $605,000,000.
- What was the lead product of cCAM Biotherapeutics?
- The lead product of cCAM Biotherapeutics was CM-24, a humanized monoclonal antibody targeting the immune checkpoint protein CEACAM1, designed to stimulate the patient's own immune system to attack tumor cells.
- What was the total amount raised by cCAM Biotherapeutics before its acquisition?
- cCAM Biotherapeutics raised a total of $8,000,000 USD.
- When did cCAM Biotherapeutics initiate a Phase 1 trial for CM-24?
- In April 2015, cCAM Biotherapeutics announced the initiation of a Phase 1 trial for CM-24, a novel immune checkpoint inhibitor for cancer immunotherapy.
- Which investor participated in cCAM Biotherapeutics' Seed round?
- Arkin Holdings participated in cCAM Biotherapeutics' Seed round in September 2012.
- How many employees did cCAM Biotherapeutics have?
- cCAM Biotherapeutics had 1-10 employees.
- When was cCAM Biotherapeutics founded?
- cCAM Biotherapeutics was founded in 2010.
Team · 1
Professor Gal Markel
Founder · Founder
Sectors & technology
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
Biologicals
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2B
Tags
therapeuticscancerpharmaceuticalsimmunologytreatmentspharma-companies
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | ccam-bio.com/ |
|---|---|
| linkedin.com/company/6015961 |
Identifiers & details
| Founded | 2010 |
|---|---|
| Status reason | Acquired (Inactive) by Merck on Jul 2015 - closed due to acquisition |
Acquisitions & public offerings
Acquired by Merck 2015-07 $605.0M
Radar intelligence
Patents
| EPO | 4 |
|---|
Web history (Wayback)
| Domain | ccam-bio.com |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 514396464 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 2010-01-26 |
| Purpose | לעסוק בסוגי עיסוק שפורטו בתקנון |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 2026 |
| Active charges / liens | 0 |
| Registry events | 5 — annual_report (2), people (3) |
| Registered address | החרש 34 הוד השרון |
Recent registry events
| Date | Event |
|---|---|
| 2026-03-31 | דו~ח שנתי-שינוי בהוראות בתקנון |
| 2026-03-31 | דו~ח שנתי-עדכון מען דיגיטלי |
| 2026-03-31 | עדכון בעלי תפקידים |
| 2026-02-04 | עדכון דירקטורים-הסרת דירקטור |
| 2026-02-03 | עדכון דירקטורים-הוספת דירקטור |